Study to measure how well aspirin is able to reduce the number of platelets in the blood of patients with reactive thrombocytosis caused by pseudomyxoma peritonei (a rare form of cancer that affects the lining of the abdomen and pelvis)
Not Applicable
- Conditions
- CancerPseudomyxoma peritonei
- Registration Number
- ISRCTN41194672
- Lead Sponsor
- Hampshire Hospitals NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 156
Inclusion Criteria
1. Patients >18 years of age
2. Diagnosis of Pseudomyxoma Peritonei
3. Patients undergoing CRS and HIPEC
4. Post-operative platelet count of >1000 x 10^9/L
Exclusion Criteria
1. Patients <18 years of age
2. Having CRS and HIPEC for other conditions apart from Pseudomyxoma Peritonei
3. Allergic to aspirin
4. On other antiplatelet or drugs that affect platelet function e.g. NSAIDs
5. Ischaemic vascular events, percutaneous coronary intervention, or coronary artery bypass within the last 12 months
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Aspirin resistance measured at baseline, 4 hours post aspirin administration, day 1, day 3, day 5 and day 14 or day of discharge, which ever comes first using the VerifyNowTM.
- Secondary Outcome Measures
Name Time Method Determine if there are any thromboembolic events at 60 days post-operatively via completion of a questionnaire.